Welichem Biotech, Inc.
| TSX Venture Exchange: WBI
Welichem Biotech, Inc. is a development stage drug company. It engages in discovery and development of novel small molecule therapeutics. Welichem Biotech focuses on new therapeutics for autoimmune/inflammatory diseases and cancers. The company is dedicated to research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its unique anticancer drug candidate, WBI-2100 and its derivatives. Welichem Biotech was founded by John M. Webster and Genhui Chen in 1995 and is headquartered in Burnaby, Canada.